KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
Posted on18 Sep 2014
Comments0
Course Syllabus & Orientation:
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Executive Program
- Advance Diploma Program
- Advance Diploma Dual Specialization
- Certificate Courses – 1 Month
- Biotech Regulatory Affairs & Strategic Management
- Pharma Product Management
- Pharma Project Management
- Medical Devices Regulation
- Drug Regulatory Affairs
- Latam DRA
- African DRA
- GCC Regulatory Affairs
- ASEAN DRA
- European DRA
- USFDA Regulation
- GMP & GMP Audit
- Dossier Training
- Drug Discovery to Commercialization
- QA Documentation
- IP Management
- Short Courses / Books / White Paper
- Admission Process
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Verify Course Certificate
- Request for Course Completion Certificate
- Knowledge Base
- Contact
KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
Our Popular Courses
Recent Articles
- 2018’s Top 6 pharma global brands in sales
- Insignht on USFDA approval of Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women
- Johnson & Johnson’s Spravato (esketamine) For Treatment-Resistant Depression
- GSK’s Advair Loss of Exclusivity (LOE) and Mylan’s Wixela Inhub generic entry
- Takeda subsidiary Millennium Pharmaceuticals Inc, sues Aurobindo to block generic Velcade
- US FDA grants breakthrough therapy status to AbbVie’s venetoclax in combo with obinutuzumab for untreated adults patients with CLL
- In India, insight on the ban of OTC sale of skin medications containing hydroquinone from April 1
- In India, Prices of 390 cancer drugs slashed by upto 87%
- Roche receives US FDA approval for Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
- Ascent Meditech launches www.flamingohealth.com, e-commerce platform